Article Cites HemogloBind™ in Parkinson’s Disease Study
MONMOUTH JUNCTION, NJ, January 24, 2017 -- BiotechSupport Group reports on a recent research article
describing the simplicity and efficiency of their hemoglobin depletion technologyfor improving the signal from
whole blood protein immunoblot analysis. Thecitation is:
Suna, et al. "Blood RNA biomarkers in prodromal PARK4 and REM sleepbehavior disorder show role of
complexin-1 loss for risk of Parkinson'sdisease." Disease Models & Mechanisms (2017): dmm-028035.
this study, Parkinson’s disease progression is investigated through the accumulationand aggregation of the
lipid-binding SNARE complex component alpha-synuclein(SNCA) which underlies vulnerability and defines its
stages. The authorsstudied blood samples from a new large pedigree with SNCA geneduplication
(PARK4 mutation) , to identify effects of SNCA gain-of-function aspotential disease biomarkers. The article
states “For protein extraction fromthe EDTA tubes, 300 μl blood were lysed with equal amount of 1% SDS-RIPA
buffer[50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Igepal CA-630(Sigma), 0.5%
sodium deoxycholate, 0.1% SDS, 1 mM PMSF and one tablet CompleteProtease Inhibitor Cocktail (Roche)] and
sonicated for 10 sec. The blood lysates were rotated at 4 °C for 30 min and centrifuged at 4 °C for 30 min.
Thesupernatants were depleted in hemoglobin content using a commercial kit(HemogloBind, Biotech) following
the manufacturer’s instructions”. After hemoglobin depletion, immunoblot analysis identified that PARK4 blood
showedupregulation of alpha-synuclein monomer, with no high molecular weightaggregates.
“Because of the large amount of hemoglobin in whole blood, itsvery exciting to see that HemogloBind™ can
reduce the presence of hemoglobinsufficient for such precise immunoblot analysis.” states Swapan Roy,
Ph.D.,President and Founder of Biotech Support Group.
For more information on HemogloBind™, visit:
Matthew Kuruc 732-274-2866, firstname.lastname@example.org